Introduction
Objectives
Methods
Search Methods
Selection Criteria
Types of Outcome Measures
Data Collection and Analysis
Results
Different Medical Applications of CoQ10 and CoQH2 Supplementation
Effects of CoQ10 and CoQH2 on Cardiovascular Diseases
Author | Year | Probands included | Duration supplementation/(study) [weeks] | Daily intake (mg/d) | Effect | Reduced cardiovascular mortality (%) | |
---|---|---|---|---|---|---|---|
CoQ10 | Judy et al. [16] | 1993 | 20 | 6/(6) | 100 | Improved echocardiogram and improved EF | |
Morisco et al. [17] | 1993 | 641 | 52/(52) | 160 | Reduced time of hospitalisation | ||
Chello et al. [18] | 1994 | 40 | 1/(1) | 150 | No reduced cardiovascular mortality | 0 | |
Morisco et al. [19] | 1994 | 6 | 4/(8) | 200 | Improved echocardiogram Improved EF | ||
Singh et al. [20] | 1998 | 144 | 4/(4) | 120 | Reduced cardiovascular mortality | 15.90 | |
Berman et al. [21] | 2004 | 32 | 12/(12) | 60 | Improved clinical status, improved 6-min walk test and improved NYHA class | ||
Chew et al. [22] | 2008 | 74 | 24/(24) | 160 | No improved E/e´ ratio | ||
Makhija et al. [23] | 2008 | 30 | 7/(7) | 165 | Reduced time of hospitalisation | ||
Kuimov et al. [24] | 2013 | 8/(8) | 60 | Improved clinical status | |||
Mortensen et al. [25••] | 2014 | 420 | 16/(104) | 300 | Improved NYHA class, reduced time of hospitalisation and reduced cardiovascular mortality | 18.00 | |
Aslanabadi et al. [26] | 2016 | 100 | 0.14/(0.14) | 300 | Reduced cardiovascular mortality | 2.00 | |
Mortensen et al. [27] | 2019 | 231 | 12/(96) | 300 | Improved NYHA class, improved EF, reduced time of hospitalisation and reduced cardiovascular mortality | 11.00 | |
Sobirin et al. [28] | 2019 | 28 | 4/(4) | 300 | Improved E/e´ ratio | ||
Khan et al. [29] | 2020 | 123 | 0.14/(0.14) | 400 | Reduced BNPs and reduced time of hospitalisation | ||
CoQ10 & Selenium | Kuklinski et al. [30] | 1994 | 61 | 52/(52) | 100 | Reduced cardiovascular mortality | 20.00 |
Alehagen et al. [31••] | 2013 | 443 | 260/(520) | 200 | Improved echocardiogram, improved EF, reduced BNPs and reduced cardiovascular mortality | 6.70 | |
Alehagen et al. [32] | 2015 | 443 | 260/(520) | 200 | Reduced cardiovascular mortality | 17.90 | |
Alehagen et al. [33] | 2015 | 443 | 148/(270) | 200 | Reduced cardiovascular mortality | 3.50 | |
Alehagen et al. [34] | 2016 | 668 | 208/(478.4) | 200 | Reduced cardiovascular mortality | 8.00 | |
Alehagen et al. [35] | 2018 | 434 | 208/(832) | 200 | Reduced cardiovascular mortality | 10.60 | |
Alehagen et al. [36] | 2021 | 213 | 208/(254) | 200 | Reduced cardiovascular mortality | 10.00 | |
Opstad et al. [37] | 2022 | 118 | 42/(520) | 200 | Reduced cardiovascular mortality | 6.00 | |
Alehagen et al. [38] | 2022 | 443 | 148/(148) | 200 | Improved echocardiogram, improved EF, reduced BNPs and reduced cardiovascular mortality | 6.70 | |
CoQH2 | Orlando et al. [39] | 2020 | 50 | 2/(26) | 400 | Improved echocardiogram, improved EF, no reduced cardiovascular mortality | 0 |
Kawashima et al. [40] | 2020 | 14 | 12/(12) | 400 | No improved echocardiogram and improved endothelial function | ||
Holmberg et al. [41] | 2021 | 43 | 1/(1) | 600 | Improved EF and no reduced cardiovascular mortality | 0 | |
Samuel et al. [42] | 2022 | 39 | 12/(12) | 300 | No Improved E/e´ratio and no reduced BNPs | ||
CoQH2 & Ribose | Pierce et al. [43•] | 2022 | 216 | 12/(12) | 600 | Improved clinical status, improved EF, reduced BNPs and no reduced cardiovascular mortality | 0 |